Participated · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.

Participated · Series A · May 2026

Waypoint Bio develops AI-driven design tools paired with an in‑house spatial pooled in vivo screening platform to create and validate CAR‑T and in vivo delivery vector designs aimed at solid tumors. The company combines computational exploration of complex design spaces with in vivo validation to learn which designs translate into meaningful effects on the tumor microenvironment. Waypoint plans to enter the clinic later this year with its first program and is using the new capital to run three CAR‑T trials in China. It is building out its platform to support additional in vivo CAR‑T targets and modalities. The company has attracted both new strategic investors and returning backers, indicating continued investor confidence as it advances clinical development.

Participated · Series B · Jun 2025

Commons Clinic operates a vertically integrated, physician-led specialty care platform that unites advanced diagnostics, personalized care pathways, and interventional procedures into a single accountable system. It launched Wholebody by Commons Clinic, a multi-specialty suite that provides comprehensive diagnostics and direct specialist treatments across musculoskeletal, cardiovascular, women’s health, metabolic, orthopedic, gastrointestinal, chronic pain, and preventive oncology care. Each Wholebody patient program includes up to three specialty consults via Commons Clinic’s national expert network and priority placement into a vetted FastPass network of primary care partners for accelerated, contiguous care. The organization emphasizes early detection, tailored prevention, and rapid intervention using technologies such as genetic testing (BRCA), coronary plaque assessment, and multi-cancer screening (Galeri) to create immediate, actionable pathways to treatment. Commons highlights its history of musculoskeletal innovation and plans to extend that playbook across cardiac, metabolic, cancer, and women’s health service lines under physician leadership. The company is based in Los Angeles and uses its vertically integrated model to reduce costs while improving specialty access and outcomes. Commons Clinic operates an integrated health system focused on spine, orthopedics, and pain management, combining physicians, branded care centers, surgical facilities and a native virtual clinic to deliver end-to-end care. Its platform converges value-based care, clinicians, ambulatory facilities and surgical centers to improve the patient experience. The company offers all-inclusive care programs for procedures including total joint replacements and spinal fusions. Founded in 2021 and based in Los Angeles, Commons Clinic raised a $19.5M Series A that brought its total funding to $33.5M. The company intends to use the proceeds to expand operations and broaden its business reach. Leadership includes co-founders Nick Aubin (CEO) and Paulo da Costa (COO); the company also added new board members following the round.

Participated · Series A · Apr 2025

Phantom Neuro develops a minimally invasive neural interface platform called Phantom X to enable intuitive control of prosthetic limbs and robotic exoskeletons. Phantom X, originally developed at the Johns Hopkins University School of Medicine, is designed to restore natural movement by making assistive devices function as seamless extensions of the body. The company reported that its ASCENT study demonstrated 94% accuracy decoding real-time gestures across 11 essential hand and wrist movements. Phantom Neuro has received FDA Breakthrough Device and TAP designations for Phantom X, which may expedite regulatory approvals. The company plans to use new funding to accelerate preclinical testing, complete first-in-human trials, pursue regulatory submissions, and expand R&D for broader control applications beyond prosthetic limbs. Phantom Neuro is headquartered in Austin, Texas and has raised $28 million in total funding to date. Phantom Neuro develops a low-power, high-accuracy system intended to provide lifelike control of robotic orthopedic technologies. The company is positioned in the neurotech sector and is based in Austin, TX. Its core product targets control interfaces for robotic orthopedics, emphasizing low power consumption and high accuracy. The article does not disclose operating metrics such as revenue or user counts. Phantom Neuro announced a $6 million expanded seed financing, which increases its total funding to $9.5 million. The funding supports the company’s continued development of its control system for robotic orthopedic applications. Phantom Neuro is a neurotechnology company based in Austin, Texas and Baltimore, Maryland that is creating a system to enable lifelike control of robotic orthopedic technologies such as prosthetic limbs and exoskeletons. Its solution combines low-risk implantable sensors, AI, and enabling software to provide control of existing and next-generation orthopedic devices. The company is led by founder and CEO Dr. Connor Glass. Phantom Neuro raised seed funding to expand its operations and business reach. The $3.26M round was led by LionBird Ventures with participation from Draper Associates, Breakout Ventures, Blackrock Neurotech, Capital Factory, and private investors. As part of the financing, LionBird partner Robert Lord will join the board and LionBird Managing Partner Ed Michael will join as a board observer.

Participated · Series A · Jan 2025

Founded in 2021 in New York, Conceivable Life Sciences is building AURA, an integrated in-vitro fertilization (IVF) lab platform that combines AI, robotics, and advanced optics to automate and standardize over 200 manual procedures spanning oocyte and sperm preparation, fertilization, embryo culture, vitrification, and thawing. The system provides end-to-end sample traceability and uses proprietary imaging (e.g., OCT) and machine-learning models to guide robotic manipulators in real time. Initial prototype work has already resulted in the birth of 18 healthy babies, and the company is running a 100-patient clinical trial with plans to gather data from an additional 120 patients this year. In a pilot deployment at Hope IVF in Mexico City, a three-person team processed roughly 2,000 IVF cycles annually with AURA, illustrating meaningful throughput and labor savings. Management aims to complete clinical trials and launch full commercial operations in the United States in early 2026. After its recent financing, the company has raised a total of $70 million to date, positioning it to move from pilot projects to commercialization.